UNII XF417D3PSL

ANHYDROUS CITRIC ACID

Unique Ingredient Identifier XF417D3PSL is listed as a ingredient substance
UniiXF417D3PSL
Preferred Substance NameANHYDROUS CITRIC ACID
Rn77-92-9
Ec201-069-1
NcitC80088
Rxcui221946
Pubchem311
Molecular FormulaC6H8O7
InchikeyKRKNYBCHXYNGOX-UHFFFAOYSA-N
SmilesOC(=O)CC(O)(CC(O)=O)C(O)=O
Unii TypeINGREDIENT SUBSTANCE
RN77-92-9
EC201-069-1
NCITC80088
RXCUI221946
PUBCHEM311
MFC6H8O7
INCHI KEYKRKNYBCHXYNGOX-UHFFFAOYSA-N
SMILESOC(=O)CC(O)(CC(O)=O)C(O)=O

Alternate Names

Dosage Forms

UNII XF417D3PSL ANHYDROUS CITRIC ACID is commonly included in medications in the following forms.

RouteDosage FormPotency
BUCCALFILM1.04 MG
IM - IVINJECTION0.33 %
INHALATIONSUSPENSION0.56 mg/2mL
INTRACARDIACINJECTION12.5 mg/5mL
INTRAMUSCULARINJECTION12.5 mg/5mL
INTRAMUSCULARINJECTION0.2 %W/V
INTRAMUSCULARINJECTION, SOLUTION0.25 %
INTRAVENOUSINJECTABLE0.2 %
INTRAVENOUSINJECTION10 MG/1ML
INTRAVENOUSINJECTION7.7 %W/V
INTRAVENOUSINJECTION, SOLUTION0.4 %W/V
INTRAVENOUSLIQUID2 MG/1ML
INTRAVENOUSLIQUID0.2 %
INTRAVENOUSPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED42.19 %
INTRAVENOUSSOLUTION, INJECTION1 %
INTRAVENOUSSOLUTION, INJECTION0.14 ADJ PH
INTRAVENOUS INFUSIONINJECTION4 MG/1ML
INTRAVENOUS INFUSIONSOLUTION, INJECTION0.53 %
INTRAVENOUS INFUSIONSOLUTION, INJECTION0.025 mg/mL
IV(INFUSION)INJECTABLE7.7 %W/V
IV(INFUSION)SOLUTION, CONCENTRATE0.6 %
IV(INFUSION)SOLUTION, INJECTION1 %
NASALSOLUTION, SPRAY0.044 %
NASALSPRAY0.058 %
NASALSPRAY, METERED0.045 %
OPHTHALMICSOLUTION0.93 MG/1ML
ORALCAPSULE, SOFT GELATIN1.64 MG
ORALCAPSULE, SOFT GELATIN LIQUID-FILLED30 MG
ORALGRANULE, FOR ORAL SUSPENSION4.9 MG
ORALLIQUID2 MG/1ML
ORALLIQUID2 mg/10mL
ORALLIQUID,EXTENDED RELEASE5.18 MG/ML
ORALPOWDER, FOR ORAL SOLUTION210 MG
ORALPOWDER, FOR ORAL SUSPENSION100 mg
ORALPOWDER, FOR ORAL SUSPENSION60 MG/PKT
ORALPOWDER, FOR SOLUTION7.99 MG
ORALPOWDER, FOR SUSPENSION10 MG/140ML
ORALSOLUTION33.18 MG/5ML
ORALSOLUTION15 mg/5 mL
ORALSOLUTION0.675 mg/15 mL
ORALSOLUTION ADJ PH
ORALSOLUTION, ELIXIR5 MG/5ML
ORALSOLUTION, LIQUID0.8 MG/1ML
ORALSUSPENSION75 MG/5ML
ORALSUSPENSION5.1 MG/5 ML
ORALSUSPENSION4.9 mg/1mL
ORALSUSPENSION2.25 mg/1.25mL
ORALSUSPENSION, DROPS2.5 MG/1ML
ORALSUSPENSION, EXTENDED RELEASE2.25 MG/1ML
ORALSYRUP22.32 MG/5ML
ORALSYRUP0.7 MG/ML
ORALTABLET20.4 MG
ORALTABLET ADJ PH
ORALTABLET, CHEWABLE8 MG
ORALTABLET, EFFERVESCENT, FOR SOLUTION839.63 MG
ORALTABLET, EXTENDED RELEASE78 MG
ORALTABLET, ORALLY DISINTEGRATING30 MG
ORALTABLET, ORALLY DISINTEGRATING ADJ PH
ORALTABLET, ORALLY DISINTEGRATING, DELAYED RELEASE8 mg
ORALTABLET, UNCOATED, LOZENGE9.8 MG
RECTALSUSPENSION0.11 %
RESPIRATORY (INHALATION)SOLUTION, SPRAY0.0003 %
RESPIRATORY (INHALATION)SUSPENSION, FOR INHALATION0.027 %
SUBCUTANEOUSINJECTION12.5 mg/5mL
SUBCUTANEOUSINJECTION0.2 %
SUBCUTANEOUSINJECTION, SOLUTION0.25 %
SUBLINGUALFILM5.56 mg
SUBLINGUALTABLET10 MG
SUBLINGUALTABLET (IMMED./COMP. RELEASE), UNCOATED, BUCCAL6 MG
SUBLINGUALTABLET, ORALLY DISINTEGRATING ADJ PH
TOPICALAEROSOL0.01 %W/W
TOPICALAEROSOL, FOAM ADJPH
TOPICALAEROSOL, FOAM ADJ PH
TOPICALCLOTH0.15 %W/W
TOPICALCREAM0.05 %W/W
TOPICALCREAM0.01 %W/W
TOPICALCREAM, EMULSION, SUSTAINED RELEASE0.18 %W/W
TOPICALEMULSION, AEROSOL FOAM0.08 %W/W
TOPICALEMULSION, CREAM0.05 %W/W
TOPICALGEL0.05 %W/W
TOPICALLOTION0.42 %W/W
TOPICALOIL0.03 %W/W
TOPICALOPHTHALMIC SUSPENSION DOSAGE FORM0.05 %W/V
TOPICALSOLUTION0.93 MG/1ML
TOPICALSOLUTION0.2 %W/W
TRANSDERMALPATCH, ELECTRICALLY CONTROLLED23 MG
TRANSMUCOSALTABLET, UNCOATED, LOZENGE11 MG

© 2020 FDA.report
This site is not affiliated with or endorsed by the FDA.